8-K: AMS Reports 19% Revenue Growth, Driven by Direct Patient Services

American Shared Hospital Services announced a 19% year-over-year revenue increase to $8.4 million for Q2 2026, primarily fueled by its Direct Patient Services segment, though net losses widened.

Summary

• Total revenue for the second quarter of 2026 increased by 19% to $8.4 million, up from $7.1 million in the prior-year period.
• Direct Patient Services revenue surged 40% to $4.9 million, driven by higher procedure volumes in Rhode Island and Mexico.
• Proton Beam Radiation Therapy (PBRT) revenue grew 22% to $2.3 million due to increased treatment volumes and reimbursement.
• International Gamma Knife revenue saw a 56% increase in the first six months of 2026, reaching $2.7 million.
• Operating cash flow was $4.4 million for the first half of 2026.
• Cash, cash equivalents, and restricted cash increased to $6.8 million as of June 30, 2026.
• The company reported a net loss of $514,000 ($0.07 per diluted share) for Q2 2026, compared to a net loss of $280,000 ($0.04 per diluted share) in Q2 2025.
• Adjusted EBITDA decreased to $1.3 million in Q2 2026 from $1.7 million in Q2 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong revenue growth in key segments offset by increased net losses and a decline in adjusted EBITDA.

Positives

• Strong 19% year-over-year revenue growth in the second quarter, reaching $8.4 million.
• Significant 40% growth in Direct Patient Services revenue to $4.9 million, indicating strong demand and operational success in key locations.
• 22% increase in Proton Beam Radiation Therapy revenue to $2.3 million, showing positive momentum in this advanced treatment area.
• 56% increase in International Gamma Knife revenue for the first half of 2026, highlighting successful international expansion.
• Operating cash flow of $4.4 million for the first six months of 2026 demonstrates healthy cash generation from operations.
• Increase in cash, cash equivalents, and restricted cash to $6.8 million from $3.7 million, strengthening the balance sheet.
• Third Amendment to Credit Agreement and Forbearance Agreement with Fifth Third Bank provides revised repayment schedule and flexibility.
• Secured $2.0 million of subordinated financing from an entity controlled by the Executive Chairman to provide additional liquidity.

Negatives

• Net loss attributable to American Shared Hospital Services increased to $514,000 in Q2 2026 from $280,000 in Q2 2025.
• Adjusted EBITDA decreased to $1.3 million in Q2 2026 from $1.7 million in Q2 2025.
• Gross margin decreased to $1.4 million in Q2 2026 from $1.6 million in Q2 2025.
• The increase in net loss was primarily due to higher legal costs ($285,000) associated with the credit agreement amendment and an increased allowance for credit losses ($909,000).

Risks

• Risks of economic and market conditions impacting financial results.
• Risk of compliance with debt covenants.
• Risks of variability of financial results between quarters.
• Risks associated with the Gamma Knife, Proton Beam Radiation Therapy, and direct patient care services businesses.
• Risks of changes to CMS reimbursement rates or methodology.
• Risks related to the timing, financing, and operations of the Company's PBRT and direct patient care services businesses.
• Risk of expanding within or into new markets.
• Risk that current and future acquisitions may negatively affect the Company's financial position.

Future Outlook

Management expresses focus on improving operating efficiencies, expanding patient access, and positioning the portfolio for sustainable long-term growth. Strategic initiatives include investing in advanced radiation therapy technologies, growing procedure volumes, expanding the installed base of technologies, prudently managing capital, and strengthening the financial position to capitalize on opportunities in precision radiation oncology.

Management Comments

• "Our second quarter results demonstrate the strength of our diversified radiation oncology platform. Our quarterly revenue growth reflects continued momentum in our Direct Patient Services business, improved Proton Beam Radiation Therapy performance and increasing contributions from our international operations. These results underscore the benefits of the strategic investments we have made over the past several years to expand our treatment capabilities and geographic footprint."
• "During the quarter, our Rhode Island facilities continued to deliver strong procedure growth while our Peru and Puebla radiation therapy centers generated another solid quarter of operating performance. In addition, higher procedure volumes and reimbursement at our Proton Beam Radiation Therapy operation contributed meaningfully to revenue growth. We remain focused on improving operating efficiencies, expanding patient access, and positioning our portfolio for sustainable long-term growth."
• "The fundamentals of our business remain strong. Demand for advanced radiation therapy continues to grow, and our portfolio of Gamma Knife, Proton Beam Radiation Therapy and radiation oncology centers positions AMS to participate across multiple areas of cancer treatment. While we continue to address our financing initiatives, our priority remains on executing our long-term growth strategy, strengthening our balance sheet and creating value for our shareholders through disciplined capital allocation and continued operational execution."
• "Our strategy remains focused on investing in advanced radiation therapy technologies that improve patient outcomes while generating attractive long-term returns. The breadth of our platform—including Gamma Knife, Proton Beam Radiation Therapy and radiation oncology centers—provides multiple avenues for sustainable growth as demand for precision cancer treatment continues to expand."
• "While we continue to address our capital structure, our operating business is performing well. We are encouraged by the continued growth in Direct Patient Services, improving international performance and strong operating cash generation during the first half of 2026. Our priorities remain clear: continue growing procedure volumes, expand our installed base of advanced radiation therapy technologies, prudently manage capital and strengthen our financial position. We believe these efforts position the Company to capitalize on attractive long-term opportunities in precision radiation oncology."

Industry Context

StockSavvy.ai notes that the strong performance in Direct Patient Services and PBRT aligns with broader industry trends of increasing demand for advanced cancer treatments and localized care delivery. The company's diversified platform across Gamma Knife, PBRT, and radiation oncology centers positions it to capture growth in various segments of the oncology market.

Legal Proceedings

• Higher legal costs of $285,000 were incurred associated with the Company's completed Third Amendment to its credit agreement with Fifth Third.

Related Party Transactions

• The Company secured $2.0 million of subordinated financing from RCS/TIG Holdings LLC, an entity controlled by the Company's Executive Chairman.

Stakeholder Impact

• Shareholders may be concerned by the widening net loss and decrease in adjusted EBITDA, despite strong revenue growth.
• Creditors may note the amendment to the credit agreement and the new subordinated financing, indicating efforts to manage debt and liquidity.
• Employees and patients in Rhode Island, Peru, and Puebla may benefit from continued strong performance and expansion of services in these regions.

Next Steps

• Continue growing procedure volumes.
• Expand the installed base of advanced radiation therapy technologies.
• Prudently manage capital.
• Strengthen the financial position.
• Pursue longer-term capital structure alternatives.

Key Dates

Recommendation

The strong revenue growth and strategic investments are positive, but the widening net loss, decreased adjusted EBITDA, and increased allowance for credit losses present significant concerns. The company is actively addressing its capital structure, which introduces uncertainty. A 'hold' recommendation reflects the balance between growth potential and financial headwinds.

Keywords

stereotactic radiosurgery, radiation therapy, cancer treatment, Proton Beam Radiation Therapy, Gamma Knife, Direct Patient Services, medical equipment leasing, oncology